Silk Road Medical (SILK)
(Real Time Quote from BATS)
$27.08 USD
+0.02 (0.07%)
Updated Jul 12, 2024 02:26 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Income Statements
Fiscal Year end for Silk Road Medical, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 177 | 139 | 101 | 75 | 63 |
Cost Of Goods | 50 | 38 | 25 | 21 | 16 |
Gross Profit | 127 | 101 | 76 | 54 | 47 |
Selling & Adminstrative & Depr. & Amort Expenses | 186 | 153 | 124 | 97 | 75 |
Income After Depreciation & Amortization | -59 | -52 | -47 | -43 | -28 |
Non-Operating Income | 10 | 2 | 0 | 0 | -19 |
Interest Expense | 7 | 5 | 3 | 4 | 5 |
Pretax Income | -56 | -55 | -50 | -47 | -52 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -56 | -55 | -50 | -47 | -52 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -56 | -55 | -50 | -47 | -52 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -62 | -50 | -45 | -41 | -27 |
Depreciation & Amortization (Cash Flow) | -2 | 2 | 3 | 2 | 1 |
Income After Depreciation & Amortization | -59 | -52 | -47 | -43 | -28 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 38.80 | 35.78 | 34.64 | 32.97 | 22.96 |
Diluted EPS Before Non-Recurring Items | -1.44 | -1.54 | -1.44 | -1.44 | -1.36 |
Diluted Net EPS (GAAP) | -1.44 | -1.54 | -1.44 | -1.44 | -2.28 |
Fiscal Year end for Silk Road Medical, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 48.48 | 47.27 | 44.44 | 45.30 |
Cost Of Goods | NA | 11.98 | 12.47 | 12.05 | 13.00 |
Gross Profit | NA | 36.50 | 34.80 | 32.39 | 32.29 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 51.44 | 49.17 | 46.06 | 46.61 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -14.94 | -14.37 | -13.67 | -14.32 |
Non-Operating Income | NA | 2.52 | 3.10 | 2.62 | 2.54 |
Interest Expense | NA | 1.72 | 1.73 | 1.73 | 1.71 |
Pretax Income | NA | -14.14 | -13.01 | -12.79 | -13.48 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -14.14 | -13.01 | -12.79 | -13.48 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -14.14 | -13.01 | -12.79 | -13.48 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 39.26 | 39.05 | 38.87 | 38.77 |
Diluted EPS Before Non-Recurring Items | NA | -0.36 | -0.33 | -0.33 | -0.35 |
Diluted Net EPS (GAAP) | NA | -0.36 | -0.33 | -0.33 | -0.35 |